Abstract
With age, abdominal organs and tissue undergo important changes. For example, liver volume declines, fatty replacement increases in the pancreas, and patients become more vulnerable to age-related diseases such as non-alcoholic fatty liver disease, alcoholic liver disease, hepatitis, fibrosis, cirrhosis, type two diabetes, cancer, gallstones and inflammatory pancreatic disease. Detecting early abdominal aging and identifying factors associated with this phenotype could help delay the onset of such diseases. In the following, we built the first abdominal age predictor by training convolutional neural networks to predict age from 45,552 liver magnetic resonance images [MRIs] and 36,784 pancreas MRIs (R-Squared=73.3±0.6; root mean squared error=3.70±0.03). Attention maps show that the prediction is driven not only by liver and pancreas anatomical features, but also by surrounding organs and tissue. We defined accelerated abdominal aging as the difference between abdominal age and chronological age, a phenotype which we found to be partially heritable (h_g2=26.3±1.9%). Accelerated abdominal aging is associated with seven single nucleotide polymorphisms in six genes (e.g PNPT1, involved in RNA metabolic processes). Similarly, it is associated with biomarkers (e.g body impedance), clinical phenotypes (e.g chest pain), diseases (e.g hypertension), environmental (e.g smoking) and socioeconomic (e.g education) variables, suggesting potential therapeutic and lifestyle interventions to slow abdominal aging. Our predictor could be used to assess the efficacy or emerging rejuvenating therapies on the abdomen.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NIEHS R00 ES023504 NIEHS R21 ES25052. NIAID R01 AI127250 NSF 163870 MassCATS, Massachusetts Life Science Center Sanofi The funders had no role in the study design or drafting of the manuscript(s).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Harvard internal review board (IRB) deemed the research as non-human subjects research (IRB: IRB16-2145).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We used the UK Biobank (project ID: 52887). The code can be found at https://github.com/Deep-Learning-and-Aging. The results can be interactively and extensively explored at https://www.multidimensionality-of-aging.net/. We will make the biological age phenotypes available through UK Biobank upon publication. The GWAS results can be found at https://www.dropbox.com/s/59e9ojl3wu8qie9/Multidimensionality_of_aging-GWAS_results.zip?dl=0.
https://github.com/Deep-Learning-and-Aging
https://www.multidimensionality-of-aging.net/
https://www.dropbox.com/s/59e9ojl3wu8qie9/Multidimensionality_of_aging-GWAS_results.zip?dl=0